Indo Us Biotech Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Thu Apr 23 2026

Indo Us Biotech (INDOBIOTECH) Q4 FY26 results are expected on May 2026. Analyst consensus estimates revenue at Rs 95–110 Cr and PAT at Rs 10–15 Cr for the January to March 2026 quarter. This article covers what analysts are expecting, five key growth factors to watch, risks to the investment thesis, and a complete FAQ section for investors.

Click Here — Get Free SEBI-registered Research on Indo Us Biotech on Univest.

Table of Contents

Indo Us Biotech Q4 FY26 Results Overview

Company	Indo Us Biotech
NSE Ticker	INDOBIOTECH
Sector	Biotech / Animal Health / Vaccines
CMP (April 2026)	Rs 1,280
52-Week High	Rs 1,900
52-Week Low	Rs 1,000
Q4 FY26 Results Date	May 2026
Revenue Estimate	Rs 95–110 Cr
PAT Estimate	Rs 10–15 Cr
Key Margin Metric	EBITDA 14–17%

Data from NSE/BSE and analyst estimates. April 2026. Verify before investing.

Track live Indo Us Biotech price and analyst targets on the Univest Screener.

What to Expect from Indo Us Biotech Q4 FY26

Get Free Investment Predictions on Univest — Tap Here.

Indo Us Biotech is expected to report Q4 FY26 results on May 2026. The board meeting will consider the financial results for the quarter ended March 31, 2026. Revenue is estimated at Rs 95–110 Cr and PAT at Rs 10–15 Cr, with EBITDA 14–17% as the key operational metric. India’s Q4 FY26 earnings season runs through April and May 2026, with the Nifty 50 aggregate PAT growth expected at 8 to 12 percent YoY. Key themes across the season include margin recovery, capex normalisation, and FY27 guidance.

Budget 2026-27 Impact on Biotech

Union Budget 2026-27 continued strong support for the Biotech sector through PLI scheme continuation, infrastructure capex of Rs 11.21 lakh crore, and consumption-led demand incentives. The US 26 percent reciprocal tariff announced April 2, 2026 has created FII outflow pressure across Indian equities, but domestic policy support provides a buffer for Indo Us Biotech’s core business segments heading into Q4 FY26.

Q4 FY26 Estimates Table

Metric	Q4 FY26 Estimate	Q4 FY25 Actual	YoY Change
Revenue	Rs 95–110 Cr	Verify on NSE	10–15% YoY est
PAT	Rs 10–15 Cr	Verify on NSE	12–18% YoY est
EBITDA	EBITDA 14–17%	Verify on NSE	Stable to improving

Estimates from analyst consensus. Actual results may differ. Verify before investing.

5 Key Growth Factors to Watch in Indo Us Biotech Q4 FY26 Results

1. Revenue Growth in Constant Currency

Analysts tracking Indo Us Biotech will monitor Revenue Growth in Constant Currency closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

2. Deal TCV and Pipeline Conversion

Analysts tracking Indo Us Biotech will monitor Deal TCV and Pipeline Conversion closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

3. EBIT Margin Trajectory

Analysts tracking Indo Us Biotech will monitor EBIT Margin Trajectory closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

4. GenAI Service Revenue Monetisation

Analysts tracking Indo Us Biotech will monitor GenAI Service Revenue Monetisation closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

5. Attrition and Hiring Cost Normalisation

Analysts tracking Indo Us Biotech will monitor Attrition and Hiring Cost Normalisation closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the Univest Screener.

Download the Univest iOS App or Android App for live Q4 FY26 results alerts and SEBI-registered analyst research on Indo Us Biotech.

5 Risk Factors for Indo Us Biotech Investors

1. US Tariff Macro Headwinds and FII Outflows

US Tariff Macro Headwinds and FII Outflows is a key monitorable for Indo Us Biotech investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

2. Valuation Requiring Consistent Execution

Valuation Requiring Consistent Execution is a key monitorable for Indo Us Biotech investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

3. Competition — Domestic and Global

Competition — Domestic and Global is a key monitorable for Indo Us Biotech investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

4. Raw Material and Input Cost Volatility

Raw Material and Input Cost Volatility is a key monitorable for Indo Us Biotech investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

5. Macro Sensitivity — GDP and Rate Cycle

Macro Sensitivity — GDP and Rate Cycle is a key monitorable for Indo Us Biotech investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.

Analyst Ratings and Targets for Indo Us Biotech

Brokerage	Rating	12M Target	Thesis
MOFSL	Buy	Rs 1,536	FY27 earnings recovery; Biotech sector leadership
YES Securities	Buy	Rs 1,561	Quality execution; accumulate at support
Kotak Institutional	Add	Rs 1,472	Monitor Q4 FY26 result vs estimates closely
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity

Analyst targets are estimates as of April 2026. These are not guaranteed returns. Verify before investing.

Subscribe to Univest Pro for SEBI-registered analyst entry, target, and stop-loss recommendations.

Q4 FY26 Earnings Calendar — Other Major Companies

Company	Results Date
Infosys	Apr 23, 2026
IndusInd Bank	Apr 24, 2026
InterGlobe Aviation (IndiGo)	Apr 28, 2026
Indo Us Biotech	May 2026

For the full Q4 FY26 results calendar, visit Univest Blogs.

Discover Biotech stocks with strong Q4 FY26 performance on the Univest Screener.

Conclusion

Indo Us Biotech (INDOBIOTECH) Q4 FY26 results on May 2026 are a key earnings event for investors in the Biotech / Animal Health / Vaccines sector. Analyst consensus expects revenue of Rs 95–110 Cr and PAT of Rs 10–15 Cr. A beat versus estimates supports the bull case for re-rating toward analyst targets. A miss increases downside risk. Monitor results live and get instant research alerts on the Univest Screener or the Univest App. For more Q4 FY26 results previews, visit Univest Blogs.

Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. All analyst estimates and targets are sourced from publicly available research and may change. Verify all numbers on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: When is Indo Us Biotech Q4 FY26 results date?

Indo Us Biotech Q4 FY26 results are expected on May 2026. The board meeting will consider the quarterly financials for January to March 2026. Track the announcement on NSE or the Univest Screener.

Q: What is Indo Us Biotech Q4 FY26 revenue estimate?

Analyst consensus estimates Indo Us Biotech Q4 FY26 revenue at Rs 95–110 Cr. Actual results may differ. Verify with MOFSL, YES Securities, or Kotak research once declared on May 2026.

Q: What is Indo Us Biotech Q4 FY26 PAT estimate?

Analyst consensus expects Indo Us Biotech Q4 FY26 PAT at Rs 10–15 Cr. This is an estimate based on publicly available research — actual results may vary. Track results live on the Univest Screener.

Q: Is Indo Us Biotech a buy before Q4 FY26 results?

This article does not constitute investment advice. Investors should review actual Q4 FY26 results before making investment decisions. A beat versus estimates typically supports price recovery; a miss increases downside risk. Consult a SEBI-registered financial advisor.

Q: What is Indo Us Biotech current share price?

Indo Us Biotech (NSE: INDOBIOTECH) is trading at Rs 1,280 as of April 2026. Track the live price, FII or DII flows, and analyst ratings on the Univest Screener at univest.in/screeners.

Q: What are the key factors to watch in Indo Us Biotech Q4 FY26?

Key factors for Indo Us Biotech Q4 FY26 include: Revenue Growth in Constant Currency, Deal TCV and Pipeline Conversion, EBIT Margin Trajectory. Track all these metrics on the Univest Screener.

Q: What is Indo Us Biotech FY27 outlook?

Analyst consensus expects Indo Us Biotech to deliver 12 to 18 percent earnings growth in FY27 — contingent on macro stabilisation, sector tailwinds, and execution on the growth plan outlined in Q4 FY26 management commentary.

Q: Where to track Indo Us Biotech Q4 FY26 results live?

Track Indo Us Biotech Q4 FY26 results live on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for instant research alerts when results are declared on May 2026.